Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05373277
- Locations
- 🇫🇮
Department of Clinical Pharmacology, Helsinki, Finland
Fruquintinib DDI Study With P-gp and BCRP Substrates
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 32
- Registration Number
- NCT05368805
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05236530
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Rania Mahmoud Mohamed
- Target Recruit Count
- 38
- Registration Number
- NCT05197517
- Locations
- 🇪🇬
Future Research Center (FRC), Cairo, Egypt
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05176314
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
🇺🇸QPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05088343
- Locations
- 🇨🇳
Xueying General Ding, Shanghai, Shanghai, China
A Study of Lazertinib (JNJ-73841937) in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05076877
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT05064488
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 13
- Registration Number
- NCT05045638
- Locations
- 🇺🇸
Covance Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States
Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of Simvastatin and Rosuvastatin
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 362
- Registration Number
- NCT04921657
- Locations
- 🇭🇰
Brian Tomlinson, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.